Dinutuximab Beta — Drug Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

4 Recruiting

2 Completed trials

7 Sponsors

15 Countries

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 3 Phase II: 2 Phase I/II: 2 Phase I (Other): 1

Indications tested

Neuroblastoma 4 Central nervous system neuroblastoma 1

Sponsors using this IMP

The University Of Birmingham 2 GPOH gGmbH 1 Institut Gustave Roussy 1 IRCCS Istituto Giannina Gaslini 1 Prinses Maxima Centrum voor Kinderoncologie B.V. 1 University Of Cologne 1 Uniwersytet Jagiellonski Collegium Medicum 1

All trials

8 total

BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending

2024-516115-24-00 Phase I/II 10 countries The University Of Birmingham
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending

2024-517295-37-00 Phase III 1 country University Of Cologne
International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting

2024-515245-42-00 Phase I (Other) 4 countries GPOH gGmbH
Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting

2023-509673-22-00 Phase I/II 7 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Phase III 13 countries Institut Gustave Roussy
TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neurob… Recruiting

2024-519089-32-02 Phase II 1 country IRCCS Istituto Giannina Gaslini
Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to … Ended

2024-513141-37-00 Phase III 1 country Uniwersytet Jagiellonski Collegium Medicum
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended

2024-518931-12-00 Phase II 5 countries The University Of Birmingham

Showing 1–8 of 8 trials

← All drugs A–Z